Cargando…

Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates

Human P‐glycoprotein (P‐gp) is a multispecific drug‐efflux transporter, which plays an important role in drug resistance and drug disposition. Recent cryo‐electron microscopy structures confirmed its rotationally symmetric architecture, which allows dual interaction with ATP and substrates. We here...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasim, Fauzia, Schmid, Diethart, Szakács, Gergely, Sohail, Azmat, Sitte, Harald H., Chiba, Peter, Stockner, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105846/
https://www.ncbi.nlm.nih.gov/pubmed/32232949
http://dx.doi.org/10.1002/prp2.572
_version_ 1783512487511982080
author Nasim, Fauzia
Schmid, Diethart
Szakács, Gergely
Sohail, Azmat
Sitte, Harald H.
Chiba, Peter
Stockner, Thomas
author_facet Nasim, Fauzia
Schmid, Diethart
Szakács, Gergely
Sohail, Azmat
Sitte, Harald H.
Chiba, Peter
Stockner, Thomas
author_sort Nasim, Fauzia
collection PubMed
description Human P‐glycoprotein (P‐gp) is a multispecific drug‐efflux transporter, which plays an important role in drug resistance and drug disposition. Recent cryo‐electron microscopy structures confirmed its rotationally symmetric architecture, which allows dual interaction with ATP and substrates. We here report the existence of two distinct, symmetry‐related outer gates. Experiments were aided by availability of the X‐ray structure of a homodimeric eukaryotic homolog of P‐gp from red alga (CmABCB1), which defined the role of an apical tyrosine residue (Y358) in outer gate formation. We mutated analogous tyrosine residues in each half of the human full‐length transporter (Y310, Y953) to alanine. These mutants were introduced in engineered transporters which bind rhodamine 123 in one of two symmetry‐related binding modes only. Outer gate dysfunction was detected by a loss of active transport characteristics, while these mutants retained the ability for outward downhill transport. Our data demonstrate that symmetric tyrosine residues Y310 and Y953 are involved in formation of two distinct symmetry‐related outer gates, which operate contingent on the rhodamine 123 binding mode. Hence, the rotationally symmetric architecture of P‐gp, which determines duality in ATP binding and rhodamine 123 interaction, also forms the basis for the existence of two independently operating outer gates.
format Online
Article
Text
id pubmed-7105846
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71058462020-04-01 Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates Nasim, Fauzia Schmid, Diethart Szakács, Gergely Sohail, Azmat Sitte, Harald H. Chiba, Peter Stockner, Thomas Pharmacol Res Perspect Original Articles Human P‐glycoprotein (P‐gp) is a multispecific drug‐efflux transporter, which plays an important role in drug resistance and drug disposition. Recent cryo‐electron microscopy structures confirmed its rotationally symmetric architecture, which allows dual interaction with ATP and substrates. We here report the existence of two distinct, symmetry‐related outer gates. Experiments were aided by availability of the X‐ray structure of a homodimeric eukaryotic homolog of P‐gp from red alga (CmABCB1), which defined the role of an apical tyrosine residue (Y358) in outer gate formation. We mutated analogous tyrosine residues in each half of the human full‐length transporter (Y310, Y953) to alanine. These mutants were introduced in engineered transporters which bind rhodamine 123 in one of two symmetry‐related binding modes only. Outer gate dysfunction was detected by a loss of active transport characteristics, while these mutants retained the ability for outward downhill transport. Our data demonstrate that symmetric tyrosine residues Y310 and Y953 are involved in formation of two distinct symmetry‐related outer gates, which operate contingent on the rhodamine 123 binding mode. Hence, the rotationally symmetric architecture of P‐gp, which determines duality in ATP binding and rhodamine 123 interaction, also forms the basis for the existence of two independently operating outer gates. John Wiley and Sons Inc. 2020-03-31 /pmc/articles/PMC7105846/ /pubmed/32232949 http://dx.doi.org/10.1002/prp2.572 Text en © 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Nasim, Fauzia
Schmid, Diethart
Szakács, Gergely
Sohail, Azmat
Sitte, Harald H.
Chiba, Peter
Stockner, Thomas
Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates
title Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates
title_full Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates
title_fullStr Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates
title_full_unstemmed Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates
title_short Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates
title_sort active transport of rhodamine 123 by the human multidrug transporter p‐glycoprotein involves two independent outer gates
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105846/
https://www.ncbi.nlm.nih.gov/pubmed/32232949
http://dx.doi.org/10.1002/prp2.572
work_keys_str_mv AT nasimfauzia activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates
AT schmiddiethart activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates
AT szakacsgergely activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates
AT sohailazmat activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates
AT sitteharaldh activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates
AT chibapeter activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates
AT stocknerthomas activetransportofrhodamine123bythehumanmultidrugtransporterpglycoproteininvolvestwoindependentoutergates